Jackson P.  Tai net worth and biography

Jackson Tai Biography and Net Worth

Jackson Peter Tai is an Independent Director of MasterCard Inc., Mr. Tai brings to the Board extensive global executive experience in payments and retail banking, including as former CEO of a Singapore-based bank and as a director of several global financial institutions. Mr. Tai’s experience as a CFO, his extensive experience as a member of numerous public company audit committees and his career in investment banking provide valuable financial understanding. His service as a director of technology-focused retail and telecommunications companies provides valuable consumer and digital and innovation insight. Board committees • Audit • Nominating & Corporate Governance Current public company boards • Eli Lilly and Company (audit; finance; and directors & corporate governance committees) • HSBC Holdings plc (group risk committee chair; group financial system vulnerabilities committee chair; group audit and nominations & corporate governance committees) Additional positions • Director, Metropolitan Opera • Trustee, Rensselaer Polytechnic Institute • Former director, Canada Pension Plan Investment Company • Former director, Cassis International Pte. Ltd. (payments technology company) • Former director, privately held Russell Reynolds Associates, Inc. • Former director, Brookstone Inc. Previous experience • Vice chairman and CEO, DBS Group and DBS Bank Ltd. (2002-2007) • Prior executive positions at DBS Group (1999-2002), including President and COO and CFO • Senior management positions at Investment Banking Division, J.P. Morgan & Co. Incorporated (New York, Tokyo and San Francisco) (1974-1999) Past public company boards • Royal Philips N.V. • Bank of China, Limited • DBS Group and DBS Bank Ltd. • ING Groep N.V. • Singapore Airlines Limited

What is Jackson P. Tai's net worth?

The estimated net worth of Jackson P. Tai is at least $36.97 million as of August 12th, 2022. Mr. Tai owns 62,857 shares of Eli Lilly and Company stock worth more than $36,969,345 as of December 6th. This net worth evaluation does not reflect any other investments that Mr. Tai may own. Learn More about Jackson P. Tai's net worth.

How do I contact Jackson P. Tai?

The corporate mailing address for Mr. Tai and other Eli Lilly and Company executives is LILLY CORPORATE CENTER, INDIANAPOLIS IN, 46285. Eli Lilly and Company can also be reached via phone at (317) 276-2000 and via email at [email protected]. Learn More on Jackson P. Tai's contact information.

Has Jackson P. Tai been buying or selling shares of Eli Lilly and Company?

Jackson P. Tai has not been actively trading shares of Eli Lilly and Company during the last ninety days. Most recently, on Friday, August 12th, Jackson P. Tai bought 656 shares of Eli Lilly and Company stock. The stock was acquired at an average cost of $304.19 per share, with a total value of $199,548.64. Following the completion of the transaction, the director now directly owns 62,857 shares of the company's stock, valued at $19,120,470.83. Learn More on Jackson P. Tai's trading history.

Who are Eli Lilly and Company's active insiders?

Eli Lilly and Company's insider roster includes Anat Ashkenazi (Sr. VP & CFO ), Melissa Barnes (SVP), Enrique Conterno (SVP), Stephen Fry (SVP), Michael Harrington (VP), Susan Mahony (SVP), Johna Norton (EVP), Myles O'Neill (SVP), Derica Rice (EVP), David Ricks (CEO), Marschall Runge (Director), Aarti Shah (SVP), Christi Shaw (SVP), Jeffrey Simmons (SVP), Daniel Skovronsky (SVP), Joshua Smiley (CFO), Jackson Tai (Director), Jacob Van Naarden (Sr. VP), Alonzo Weems (SVP), Anne White (SVP), Ilya Yuffa (SVP), Donald Zakrowski (CAO), and Alfonso Zulueta (SVP). Learn More on Eli Lilly and Company's active insiders.

Are insiders buying or selling shares of Eli Lilly and Company?

In the last year, insiders at the sold shares 31 times. They sold a total of 2,569,584 shares worth more than $21,741,028,325.10. The most recent insider tranaction occured on November, 6th when CAO Donald A Zakrowski sold 670 shares worth more than $382,637.00. Insiders at Eli Lilly and Company own 0.1% of the company. Learn More about insider trades at Eli Lilly and Company.

Information on this page was last updated on 11/6/2023.

Jackson P. Tai Insider Trading History at Eli Lilly and Company

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/12/2022Buy656$304.19$199,548.6462,857View SEC Filing Icon  
4/30/2021Buy1,366$182.84$249,759.4460,649View SEC Filing Icon  
10/24/2019Buy1,861$107.49$200,038.8956,440View SEC Filing Icon  
7/26/2018Buy2,168$95.22$206,436.9653,228View SEC Filing Icon  
8/15/2016Buy5,773$80.43$464,322.3942,306View SEC Filing Icon  
8/12/2016Buy2,560$80.42$205,875.2042,110View SEC Filing Icon  
5/12/2016Buy1,080$75.75$81,810.0040,600View SEC Filing Icon  
2/1/2016Buy3,170$78.62$249,225.4039,487View SEC Filing Icon  
See Full Table

Jackson P. Tai Buying and Selling Activity at Eli Lilly and Company

This chart shows Jackson P Tai's buying and selling at Eli Lilly and Company by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Eli Lilly and Company Company Overview

Eli Lilly and Company logo
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; Foghorn Therapeutics Inc., and PRISM BioLab Co.,Ltd. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Read More

Today's Range

Now: $588.89
Low: $584.40
High: $592.88

50 Day Range

MA: $582.49
Low: $525.10
High: $619.50

2 Week Range

Now: $588.89
Low: $309.20
High: $629.97


904,362 shs

Average Volume

3,070,835 shs

Market Capitalization

$559.04 billion

P/E Ratio


Dividend Yield